Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113382 | 0.79 | MEN1 (0.48) | MEN1KMT2AGPR84L3MBTL1LMNA | |
| SCHEMBL5103982 | 0.79 | KMT2A (0.34) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL176807 | 0.74 | PAM (0.47) | KDM4EALDH1A1HPGDL3MBTL1LMNA | |
| SCHEMBL4071509 | 0.74 | — | — | |
| SCHEMBL2675960 | 0.69 | CYP1A2 (0.51) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3465163 | 0.69 | CXCR2 (0.39) | ALDH1A1 | |
| SCHEMBL5106485 | 0.68 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL128526 | 0.67 | MEN1 (0.68) | MEN1KMT2AGPR84L3MBTL1NPSR1 | |
| SCHEMBL29618255 | 0.67 | MEN1 (0.68) | MEN1KMT2AGPR84L3MBTL1NPSR1 | |
| SCHEMBL15157483 | 0.67 | PARP1 (0.50) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | MEN1 1842/4885KMT2A 699/4885GPR84 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.